EUVIMEDEUVIMED entdecken
Crossref

Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis

Feidi Chen, Raul S Gonzalez iD

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqae159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Feidi Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, US. Hauptthemen laut MEDLINE: Gastritis, Atrophic, Enterochromaffin-like Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Atrophic gastritis (AG) is characterized by atrophy of gastric glands—in particular, oxyntic glands—in the setting of chronic inflammation; it is often autoimmune. The diagnosis is confirmed by immunohistochemistry (IHC) for gastrin (to confirm biopsy site), and pathologists often use IHC for neuroendocrine markers to evaluate for enterochromaffin-like cell hyperplasia (ECL-H). The utility of neuroendocrine staining is unclear, and we undertook this study to determine whether ECL pattern provided any additional information in cases of Helicobacter-negative AG.

Methods

We reviewed clinicopathologic findings in 184 cases from 184 patients with histologic AG and no evidence of Helicobacter infection. Using neuroendocrine IHC markers, cases were divided into 3 groups: Group 1 showed complete ECL-H (both qualitative and quantitative criteria met), group 2 showed focal ECL-H (qualitative but not quantitative criteria met), and group 3 showed no ECL-H (neither criteria met).

Results

Group 1 patients were more likely to have positive autoantibody serologies (73%, P = .0007 vs group 2) and higher mean gastrin levels (700 pg/mL, P = .017 vs group 3), and only these patients developed gastric neuroendocrine tumors. Group 2 patients were more likely to take proton pump inhibitors (64%, P = .0002 vs group 1). Group 3 patients were more likely to be male (70%, P = .008 vs group 1) and to have microcytic anemia (44%, P = .022 vs group 2) and less likely to have intestinal metaplasia (50%, P = .044 vs group 1).

Conclusions

Stratification based on degree of ECL-H is not necessary for diagnosis of AG but does lead to statistically significant clinical and pathologic differences among groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastritis, AtrophicEnterochromaffin-like CellsHumansMaleFemaleMiddle AgedHyperplasiaAgedAdultGastrinsImmunohistochemistryAged, 80 and overHelicobacter InfectionsNeuroendocrine TumorsGastric MucosaStomach Neoplasms

Stichwörter der Autor:innen

ECLatrophic gastritisautoimmunehyperplasiastomach

Substanzen

Gastrins

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, US.
  • Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, US.

ORCID-Profile: Raul S Gonzalez

Zitieren

APA

Chen, F., & Gonzalez, R. S. (2025). Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae159

Vancouver

Chen F, Gonzalez RS. Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae159

BibTeX
@article{Chen2025,
  author = {Chen, Feidi and Gonzalez, Raul S},
  title = {Evaluation of enterochromaffin-like cell hyperplasia can help categorize patients with Helicobacter -negative atrophic gastritis},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqae159}
}
Kostenlos starten →